Objective: The aim of the present study was to analyze treatment outcomes and identify videourodynamic factors predictive of successful urethral onabotulinumtoxinA treatment of neurogenic and non-neurogenic detrusor underactivity (DU).
| INTRODUCTION
Chronic urinary retention due to detrusor underactivity (DU) is a debilitating bladder disorder that has considerable negative effects on quality of life as well as on health generally. In elderly patients with chronic medical disease or neurological diseases, chronic urinary retention is frequently encountered and difficult to manage. DU may be neurogenic or non-neurogenic in origin, with large post-void residual (PVR) urine volume and upper urinary tract deterioration. The pathophysiology of DU may involve neurogenic, myogenic, or bladder outlet pathologies. 1 Patients with DU usually have a diminished sensation of bladder fullness or urgency and cannot contract the detrusor sufficiently to complete bladder emptying. 2 In recent decades, urologists have used onabotulinumtoxinA injections into the urethral sphincter to treat such voiding dysfunction.
The use of onabotulinumtoxinA for the treatment of voiding dysfunction and lower urinary tract symptoms started in the late 1980s, when Dykstra and Sidi injected onabotulinumtoxinA into the external urethral sphincter in patients with spinal cord injury (SCI) to induce chemical denervation and lower detrusor sphincter dyssynergia (DSD). 3 Since then, onabotulinumtoxinA has been safely used for the treatment of several types of neurogenic spasticity in patients with SCI, multiple sclerosis (MS), and DSD. Schurch et al. reported that 21 of 24 SCI patients benefited from onabotulinumtoxinA injection. 4 Patients with DU usually cannot contract the detrusor sufficiently to void, so require abdominal straining or clean intermittent catheterization (CIC) to complete bladder emptying. 2 In patients with non-neurogenic voiding dysfunction, onabotulinumtoxinA improves voiding efficiency and detrusor contractility in some patients with urethral sphincter overactivity, non-bacterial prostatitis, and detrusor underactivity. 5, 6 Phelan et al. found that after onabotulinumtoxinA injection, 67% of patients voided smoothly and experienced substantial decreases in PVR (up to 71%) and voiding pressure decreased (up to 38%). 6 In a large series of patients with voiding dysfunction, onabotulinumtoxinA injection (50 or 100 U) resulted in excellent and improved results overall in 39% of patients, with 39% and 46% of patients in the 50 and 100 U groups, respectively, achieving such improvements. 7 OnabotulinumtoxinA injection has already been licensed for use in patients with neurogenic or non-neurogenic overactive bladder. 8 However, urethral sphincter onabotulinumtoxinA injection for voiding dysfunction remains an off-label treatment. Nevertheless, urethral sphincter onabotulinumtoxinA injections have been used in various types of voiding dysfunction in both adults and children. 9, 10 Although onabotulinumtoxinA seems effective in treating voiding dysfunction due to DU, not all patients experience successful treatment results. Voiding dysfunction may be caused by low detrusor contractility with or without high urethral sphincter resistance during voiding. In patients with DU, adequate abdominal pressure by straining and decreased urethral resistance is needed for efficient voiding.
Injecting onabotulinumtoxinA into the urethral sphincter may reduce urethral sphincter resistance, 1 but the treatment is not effective in all such patients. Therefore, in the present study we retrospectively analyzed recently treated DU patients to identify videourodynamic factors that may be used to predict the success of onabotulinumtoxinA treatment. Patients received urethral sphincter onabotulinumtoxinA injections in the operating room under light intravenous general anesthesia, as described previously. 7 Each vial of 100 U onabotulinumtoxinA was reconstituted to a volume of 4 mL with normal saline, making the concentration in the vial equivalent to 25 U/mL. A dose of 100 U onabotulinumtoxinA was injected in patients with DU who wanted to void by abdominal pressure after treatment. 4, 7 In men, onabotulinumtoxinA was injected into the urethral sphincter at the 3-, 6-, 9-, and 12-o'clock positions in approximately equal aliquots using a cystoscopic injection instrument. In women, cystoscopy was used and the axis of the urethra was determined for the proper injection position; onabotulinumtoxinA was injected into the urethral sphincter along the urethral lumen at the 3-, 6-, 9-, and 12-o'clock positions along the sides of the urethral meatus using a 23-gauge, 1-mL syringe.
| METHODS
The effects of onabotulinumtoxinA usually appeared approximately 2-3 days after urethral sphincter injections, with the maximum effect seen approximately 2 weeks after injection. 7 Patients were instructed to void spontaneously or using the Crede maneuver or abdominal straining. When difficult urination persisted, CIC was recommended, instead of an indwelling Foley catheter, until the PVR was <50% of the voided volume. The rationale for considering <50%
voiding efficiency as the cut-off value for CIC is based on urinary tract infection being more likely to occur when PVR is >200 mL.
Patients were given antibiotics for 3 days to prevent urinary tract infections due to urethral instrumentation. Because all patients were refractory to previous medication, medications to reduce urethral resistance were discontinued after onabotulinumtoxinA injections. The assessment parameters, namely the International Prostate Symptom Score (IPSS), Qmax, voided volume, and PVR, were measured at baseline and 1-3 months after onabotulinumtoxinA injection.
Patients were followed-up at an outpatient clinic monthly for up to 12 months, and the duration of the therapeutic effect was recorded as the time from injection to the time when they felt that difficult urination had returned. Videourodynamic variables were compared between patients with good and poor treatment outcomes. Changes in the assessment parameters from baseline to post-treatment evaluation were compared between patients with neurogenic and nonneurogenic DU.
| Statistical analysis
Continuous variables are expressed as the mean AE SD, whereas categorical data are presented as numbers and percentages. The significance of differences between groups was investigated using
Chi-squared tests for categorical variables and the Wilcoxon rank sum test for continuous variables. All statistical analyses were twosided and considered significant at P < .05. All calculations were performed using SPSS for Windows, version 16.0 (SPSS, Chicago, IL, USA).
| RESULTS
In all, 60 patients with urodynamically proven DU who underwent urethral onabotulinumtoxinA injection for voiding dysfunction were included in the study, 27 with non-neurogenic DU (mean age 66.6 AE 16.9 years) and 33 with neurogenic DU (mean age 55.5 AE 19.7 years). Good outcomes were reported in 36 (60%) patients and poor outcomes were reported in 24 (40%) patients. Table 1 lists patient demographics and Table 2 lists results of videourodynamic evaluation in patients with good and poor outcomes. Treatment outcome was not related to age, gender, or any urodynamic parameter, but was significantly better in patients with non-neurogenic DU (P = .039) and those
who had an open bladder neck vs non-opening bladder neck during the videourodynamic study (94.3% vs. 12.0%; P < .0001).
In patients who had a good treatment outcome after onabotulinumtoxinA injection, IPSS, Qmax, voided volume, and PVR all improved in patients with neurogenic or non-neurogenic DU. There were no significant differences in the changes in the measured parameters from baseline to post-treatment evaluation between those with neurogenic and non-neurogenic DU (Table 3 ). In addition, there was no significant difference in the duration of therapeutic effect between these 2 groups. Of those patients with a good outcome, 6 (30%) in the non-neurogenic DU group and 4 (25%) in the neurogenic DU group had a therapeutic effect that lasted for >12 months.
After urethral sphincter onabotulinumtoxinA injection, de novo urinary incontinence was reported in 12 (20%) patients with good or poor outcomes, mostly during sleep, 4 of whom had stress urinary incontinence and 8 with urgency urinary incontinence. Urinary tract End-stage bladder disease 1 2
Idiopathic etiology 10 0
There were no significant differences in the number of patients experiencing good outcomes between the neurogenic and non-neurogenic detrusor underactivity (DU) groups (P = .460). Abbreviations: CBC, cystometric bladder capacity; DU, detrusor underactivity; FSF, first sensation of filling; Pabd, abdominal pressure; Pdet, detrusor pressure; PVR, post-void residual; Qmax, maximum flow rate.
Continuous variables are expressed as the mean AE SD; categorical data are presented as n (%).
infection was noted in 12 patients, but de novo urinary tract infection was only observed in 4 (6.7%) patients overall (Table 4) .
| DISCUSSION
The findings of the present study reveal that urethral sphincter ona- DU usually occurs in patients with SCI or after pelvic surgery. The underlying diseases of chronic urinary retention due to DU include multiple system atrophy, MS, cervical or thoracic tumors, and lumbar spondylosis. 12 DU is also common in patients with old age, general weakness, and medical diseases such as diabetes mellitus, debilitating disease, cancer patients in the terminal stage, or after major surgery. 13 The treatment goal for DU is focused on reducing PVR and preventing urinary tract infection. Treatment of DU may include increasing detrusor contractility, decreasing bladder outlet resistance, or increasing cortical perception of bladder sensation. However, until now, medical treatment for DU is usually disappointing.
OnabotulinumtoxinA has been used to treat adults with nonneurogenic voiding dysfunction for more than 10 years. 7, 14 Unless indicated otherwise, data are presented as the mean AE SD. *P < .05 compared with baseline values.
a P values are for comparisons of changes from baseline between the non-neurogenic and neurogenic groups. Data are given as n (%).
(P value = .545).
not be completely satisfied with the therapeutic results of urethral sphincter onabotulinumtoxinA injection. 22, 24 Thus, patient selection is critical to treatment success.
Voiding is a complex interaction of central nervous system and peripheral neural control, detrusor contraction, bladder neck relaxation, external sphincter relaxation, and adequate pelvic floor relaxa- 
